Mitochondrial pathology in Parkinson's disease and implications for therapeutic intervention

Drug Development Research

Volumn 46, Issue 1, 1999, Pages 44-50

  Swerdlow, Russell H ^a   Parker Jr , W Davis ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Mitochondria; Mitochondrial DNA; Parkinson's disease; Therapy

Indexed keywords

ALPHA SYNUCLEIN; CATALASE; COPPER ZINC SUPEROXIDE DISMUTASE; MANGANESE SUPEROXIDE DISMUTASE; MITOCHONDRIAL DNA; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE);

ARTICLE; BRAIN MITOCHONDRION; CALCIUM HOMEOSTASIS; CELL DEATH; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA TRANSFER; NERVE CELL DEGENERATION; NERVE DEGENERATION; OXIDATIVE STRESS; PARKINSON DISEASE; RESPIRATORY CHAIN;

EID: 0032908117     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199901)46:1<44::AID-DDR7>3.0.CO;2-6     Document Type: Article

References (78)

1. Arenas J, Campos Y, Ribacoba R, Martin MA, Rubio JC, Ablanedo P, Cabello A. 1998. Complex I defect in muscle form patients with Huntington's disease. Ann Neurol 43:397-400.
2. Arizmendi JM, Skebel JM, Runswick MJ, Fearnley IM, Walker JE. 1992. Complementary DNA sequences of two 14.5 kDa subunits of NADH:ubiquinone oxidoreductase from bovine heart mitochondria: complementation of the primary structure of the complex? FEBS Lett 313:80-84.
3. Barroso N, Campos Y, Huertas R, Esteban J, Molina JA, Alonso A, Gutierrezrivas E, Arenas J. 1993. Respiratory chain enzyme activities in lymphocytes from untreated patients with Parkinson disease. Clin Chem 39:667-669.
4. Beal MF. 1995. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 38:357-366.
5. Benecke R, Strumper P, Weiss H. 1993. Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes. Brain 116:1451-1455.
6. Bindoff LA, Birch-Machin MA, Cartlidge NE, Parker WD Jr, Turnbull DM. 1991. Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease. J Neurol Sci 104:203-208.
7. Blin O, Desnuelle C, Rascol O, Borg M, Peyro Saint Paul H, Azulay JP, Bille F, Figarella D, Coulom F, Pellissier JF, Montastruc JL, Chatel M, Serratrice G. 1994. Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy. J Neurol Sci 125:95-101.
8. Brennan WA, Bird ED, Aprille JR. 1985. Regional mitochondrial respiratory activity in Huntington's disease brain. J Neurochem 44:1948-1950.
9. Burke WJ, Schmitt CA, Li SW, Lin TS, Lampe P, Johnson EM, Kristal BS. 1998. Norepinephrine (NE) MAO metabolite, but not NE, forms radicals, induces mitochondrial permeability transition and kills NE neurons: a mechanism for NE neuron death in Alzheimer's disease. Neurology 50:A409.
10. Burkhardt C, Kelly JP, Lim YH, Filley CM, Parker WD. 1993. Neuroleptic medications inhibit complex I of the electron transport chain. Ann Neurol 33:512-517.
11. Cardellach F, Marti MJ, Fernandez-Sola J, Marin C, Hoek JB, Tolosa E, Urbano-Marquez A. 1993. Mitochondrial respiratory chain activity in skeletal muscle from patients with Parkinson's disease. Neurology 43:2258-2262.
12. Cassarino DS, Fall CP, Swerdlow RH, Smith TS, Halvorsen EM, Miller SW, Parks JK, Parker WD, Bennet JP. 1997. Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. Biochim Biophys Acta 1362:77-86.
13. Cassarino S, Fall CP, Smith TS, Bennett JP Jr. 1998. Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. J Neurochem 71:295-301.
14. Damier P, Hirsch EC, Zhang P, Agid Y, Javoy-Agid F. 1993. Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience 52:1-6.
15. Dexter DT, Holley AE, Flitter WD, Slater TF, Wells FR, Daniel SE, Lees AJ, Jenner P, Marsden CD. 1994. Increased levels of lipid hydroperoxides in the Parkinsonian substantia nigra: an HPLC and ESR study. Mov Disord 9:92-97.
16. DiDonato S, Zeviani M, Giovannini P, Savarese N, Rimoldi M, Mariotti C, Girotti F, Caraceni T. 1993. Respiratory chain and mitochondrial DNA in muscle and brain in Parkinson's disease patients. Neurology 43:2262-2268.
17. Ephrussi B, Hottinger H, Chimenes AM. 1949. Action de l'acriflavine sur les levures: I. La mutation "petite clonie." Ann Inst Pasteur 76:531.
18. Forno LS, Langston JW, DeLanney LE, Irwin I, Ricuarte GA. 1986. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann Neurol 20:449-455.
19. Gavin CE, Gunter KK, Gunter TE. 1990. Manganese and calcium efflux kinetics in brain mitochondria: relevance to manganese toxicity. Biochem J 266:329-334.
20. Goldbaum LR, Orellano T, Dergal E. 1976. Mechanism of the toxic action of carbon monoxide. Ann Clin Lab Sci 6:372-376.
21. Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapira AHV. 1996. Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol 39:385-389.
22. Gu M, Cooper JM, Schapira AHV 1997. Genomic transplantation to determine the molecular basis and pathogenic role of complex I deficiency in Parkinson's disease. Mov Disord 12(Suppl 1):2.
23. Haas RH, Nasirian F, Nakano K, Ward D, Pay M, Hill R, Shults CW. 1995. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann Neurol 37:714-722.
24. Hubble JP, Cao T, Hassanein RE, Neuberger JS, Koller WC. 1993. Risk factors for Parkinson's disease. Neurology 43:1693-1697.
25. Ikebe SI, Tanaka M, Ohno K, Sato W, Hattori K, Kondo T, Mizuno Y, OzawaT. 1990. Increase of deleted mitochondrial DNA in the striatum in Parkinson's disease and senescence. Biochem Biophys Res Commun 170:1044-1048.
26. Ikebe SI, Tanaka M, Ozawa T. 1995. Point mutations of mitochondrial genome in Parkinson's disease. Mol Brain Res 28:281-295.
27. Janetzky B, Hauck S, Youdim MB, Reiderer P, Jellinger K, Pantucek F, Zochling R, Boissl KW, Reichmann H. 1994. Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. Neurosci Lett 169:126-128.
28. Johns DR, Lessell S, Miller NR. 1991. Molecularly confirmed Leber's hereditary optic neuropathy. Neurology 41(Suppl 1):347.
29. Kalra J, Rajput AH, Mantha SV, Prasad K. 1992. Serum antioxidant enzyme activity in Parkinson's disease. Mol Cell Biochem 110:165-168.
30. King MP, Attardi G. 1989. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science 246:500-503.
31. Kosel S, Lucking CB, Egensperger R, Mehraein P, Graeber MB. 1996. Mitochondrial NADH dehydrogenase and CYP2D6 genotypes in Lewy-Body parkinsonism. J Neurosci Res 44:174-183.
32. Krige D, Carrol MT, Cooper JM, Marsden CD, Schapira AHV. 1992. Platelet mitochondrial function in Parkinson's disease: the Royal Kings and Queens Parkinson Disease Research Group. Ann Neurol 32:782-788.
33. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen Jt, Schols L, Reiss O. 1998. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat Genet 18:106-108.
34. Langston JW, Ballard PA, Tetrud JW, Irwin I. 1983. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979-980.
35. Lestienne P, Nelson J, Riederer P, Jellinger K, Reichmann H. 1990. Normal mitochondrial genome in brain from patients with Parkinson's disease and complex I defect. J Neurochem 55:1810-1812.
36. Lestienne P, Nelson I, Reiderer P, Reichmann H, Jellinger K. 1991. Mitochondrial DNA in postmortem brain from patients with Parkinson's disease. J Neurochem 56:1819.
37. Mann VM, Cooper JM, Javoy-Agid F, Agid Y, Jenner P, Schapira AHV. 1990. Mitochondrial function and parental sex effect in Huntington's disease. Lancet 336:749.
38. Mann VM, Cooper JM, Krige D, Daniel SE, Schapira AH, Marsden CD. 1992a. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. Brain 115:333-342.
39. Mann VM, Cooper JM, Schapira AHV. 1992b. Quantitation of a mitochondrial DNA deletion in Parkinson's disease. FEBS 299:218-222.
40. Maraganore DM, Harding AE, Marsden CD. 1991. A clinical study of familial Parkinson's disease. Mov Disord 6:205-211.
41. Martilla RJ, Lorentz H, Rinne UK. 1988. Oxygen toxicity protecting enzymes in Parkinson's disease: increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus. J Neurol Sci 86:321-331.
42. Natsubara K, Kobayashi S, Kobayashi Y, Yamashita K, Koide H, Hatta M, Iwamoto K, Tanaka O, Kimure K. 1995. β-Carbolinium cations, endogenous MPP+ analogs, in the lumbar cerebrospinal fluid of patients with Parkinson's disease. Neurology 45:2240-2245.
43. Mizuno Y, Ohta S, Tanaka M, Takamiya S, Suzuki K, Sato T, Oya H, Ozawa T, Kagawa Y. 1989. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun 163:1450-1455.
44. Mytilineou C, Werner P, Molinari S, Di Roco A, Cohen G, Yahr MD. 1994. Impaired oxidative decarboxylation of pyruvate in fibroblasts from patients with Parkinson's disease. J Neural Transm 8:223-228.
45. Nakagawa-Hattori Y, Yoshino H, Kondo T, Mizuno Y, Horai S. 1992. Is Parkinson's disease a mitochondrial disorder? J Neurol Sci 107:22-33.
46. Newman NJ. 1993. Leber's hereditary optic neuropathy. Arch Neurol 50:540-548.
47. Nicklas WJ, Heikkila RE. 1985. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci 36:2503-2508.
48. Nicotera P, Orrenius S. 1992. Calcium and death. Ann NY Acad Sci 648:17-27.
49. 2+ level. J Immunol 154:599-609.
50. Parker WD, Boyson SJ, Parks JK. 1989. Electron transport chain abnormalities in idiopathic Parkinson's disease. Ann Neurol 26:719-723.
51. Parker WD Jr, Boyson SJ, Luder AS, Parks JK. 1990. Evidence for a defect in NADH:ubiquinone oxidoreductase (complex I) in Huntington's disease. Neurology 40:1231-1234.
52. Parkinson Study Group. 1996a. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients not requiring levodopa. Ann Neurol 39:29-36.
53. Parkinson Study Group. 1996b. Impact of deprenyl and tocopherol treatment on Parkinson s disease in DATATOP patients requiring levodopa. Ann Neurol 39:37-45.
54. Penn AMW, Roberts T, Hodder J, Allen PS, Zhu G, Martin MRW. 1995. Generalized mitochondrial dysfunction in Parkinson's disease detected by magnetic resonance spectroscopy of muscle. Neurology 45:2097-2099.
55. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehajia A, Dutra A, Pike B, Root H, Rubinstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropolous T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. 1997. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276:2045-2047.
56. 2 in cultured endothelial cells. Arch Biochem Biophys 302:348-355.
57. Saggu H, Cooksey J, Dexter D, Wells FR, Lees A, Jenner P, Marsden CD. 1989. A selective increase in particulate superoxide dismutase activity in parkinsonism substantia nigra. J Neurochem 53:692-697.
58. Sanchez-Ramos JR, Overvik E, Ames BN. 1994. A marker of oxyradical-mediated DNA damage (8-hydroxy-2′-deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain. Neurodegeneration 3:197-204.
59. Sandy MS, Langston JW, Smith MT, Di Monte DA. 1993. PCR analysis of platelet mtDNA: lack of specific changes in Parkinson's disease. Mov Disord 8:74-82.
60. Schapira AHV, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD. 1989. Mitochondrial complex I deficiency in Parkinson's disease. Lancet i:1289.
61. 1 reductase (Complex I) deficiency in Parkinson's disease. J Neurochem 55:2142-2145.
62. Schapira AHV, Holt IJ, Sweeney M, Harding AE, Jenner P, Marsden CD. 1990b. Mitochondrial DNA analysis in Parkinson's disease. Mov Disord 5:294-297.
63. Sheehan JP, Swerdlow RH, Parker WD, Miller SW, Davis RE, Tuttle JB. 1997. Altered calcium homeostasis in cells transformed by mitochondria from individuals with Parkinson's disease. J Neurochem 68:1221-1233.
64. Shoffner JM, Watts RL, Juncos JL, Torroni A, Wallace DC. 1991. Mitochondrial oxidative phosphorylation defects in Parkinson's disease. Ann Neurol 30:332-339.
65. Shoffner JM, Brown MD, Torroni A, Lott MT, Cabell MF, Mirra SS, Beal MF, Yang CC, Gearing M, Salvo R, Watts RL, Juncos JL, Hansen LA, Crain BJ, Fayad M, Reckord CL, Wallace DC. 1993. Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients. Genomics 17:171-184.
66. Stern G. 1996. Parkinson's disease: the apoptosis hypothesis. Adv Neurol 69:101-107.
67. Swerdlow R, Parks JK, Miller SW, Davis RE, Parker WD. 1995. The mitochondrial genome encodes the complex I defect in Parkinson's disease. Soc Neurosci Abstr 21:980.
68. Swerdlow RH, Parks JK, Miller SW, Tuttle JB, Trimmer PA, Sheehan JP, Bennett JP, Davis RE, Parker WD. 1996, Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol 40:663-671.
69. Swerdlow RH, Wooten GF, Parker WD. 1998. Epidemiologic support for mitochondrial genetics in Parkinson's disease. Neurology 50:A373.
70. Swerdlow RH, Parks JK, Davis JN, Cassarino DS, Trimmer PA, Currie LJ, Doherty J, Bridges S, Bennett JP, Wooten GF, Parker WD. 1998. Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson's disease family. Ann Neurol 44:873-881.
71. Tanner CM, Goldman SM. 1996. Epidemiology of Parkinson's disease. Neurol Clin 14:317-335.
72. Taylor RW, Chinnery PF, Turnbull DM, Lightowlers RN. 1997. Selective inhibition of mutant human mitochondrial DNA replication in vitro by peptide nucleic acids. Nat Genet 15:212-215.
73. Thyagarajan D, Bressman S, Shanske S, DiMauro S, Fahn S. 1997. A novel T1095C mutation in the mitochondrial 12S ribosomal RNA gene. Neurology 48:A444.
74. Werth JL, Thayer SA. 1994. Mitochondria buffer physiological calcium loads in cultured rat dorsal ganglion neurons. J Neurosci 14:348-356.
75. Wooten GF, Currie LJ, Bennett JP, Harrison MB, Trugman JM, Parker WD Jr. 1997a. Maternal inheritance in Parkinson's disease. Ann Neurol 41:265-268.
76. Wooten GF, Currie LJ, Bennett JP, Trugman JM, Harrison MB. 1997b. Maternal inheritance in two large kindreds with Parkinson's disease. Neurology 48:A333.
77. Yoshino H, Nakagawa-Hattori Y, Kondo T, Mizuno Y. 1992. Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease. J Neural Transm 41:27-34.
78. Zweig RM, Singh A, Cardillo JE, Langston JW. 1992. The familial occurrence of Parkinson's disease: lack of evidence for maternal inheritance. Arch Neurol 49:1205-1207.